Solvonis Therapeutics plc

Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for addiction and mental health disorders, targeting high-burden neuropsychiatric conditions with significant unmet needs. Headquartered in London, the company advances a differentiated pipeline of repurposed and novel compounds, primarily focusing on Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), which affect over 80 million people in the UK, US, and EU4. Its lead asset, SVN-001, is in Phase 3 trials for severe AUD in Europe and the UK, while SVN-002 prepares for Phase 2b in the US for moderate to severe AUD; a preclinical PTSD program employs serotonin-dopamine modulators to improve pro-social behavior. Solvonis also leverages an AI-supported discovery platform from a proprietary CNS library, initially targeting depression and stimulant use disorders, with recent expansions like SVN-015 into depression and U.S. patent allowances for PTSD innovations. Backed by experienced leadership including CEO Anthony Tennyson and Chief Scientific Advisor Prof. David Nutt, Solvonis employs a capital-efficient model to drive innovation in addiction, psychiatry, and emerging neurology areas. Incorporated in 2017, it plays a key role in addressing limited and ineffective current treatments for CNS disorders.